Testosterone Cypionate and Acne: When to Call the Doctor

Why Testosterone Cypionate Causes Acne

Testosterone cypionate triggers acne through a well-characterized hormonal pathway. The drug raises circulating testosterone, which 5-alpha reductase converts to dihydrotestosterone (DHT). DHT binds androgen receptors in sebaceous glands, increasing sebum production by as much as threefold compared to baseline [1]. Excess sebum clogs follicular ostia, creating an anaerobic environment where Cutibacterium acnes proliferates and triggers inflammatory cascades.

The pharmacokinetics of intramuscular cypionate contribute to the problem. A standard 200 mg injection every two weeks produces supraphysiologic testosterone peaks (often exceeding 1,200 ng/dL within 48 to 72 hours), followed by a trough that may dip below the therapeutic range [2]. These hormonal swings amplify sebaceous stimulation more than steady-state delivery methods. A 2018 pharmacokinetic analysis in the Journal of Clinical Endocrinology & Metabolism found that peak-to-trough ratios above 2.5 correlated with higher rates of androgenic side effects, including acne [3].

Not every patient on TRT develops breakouts. Genetic variation in androgen receptor sensitivity, baseline 5-alpha reductase activity, and individual sebaceous gland density all modulate risk. Men with a personal or family history of acne during puberty carry approximately twice the risk of developing acne on TRT [4]. Age matters too. Patients under 40 tend to experience more pronounced skin effects than older men on equivalent doses.

How Common Is TRT-Related Acne?

Acne is one of the most frequently reported dermatologic side effects of testosterone therapy. A meta-analysis published in Medicine (2019) pooling 3,236 hypogonadal men across 15 randomized controlled trials reported acne in 26.1% of testosterone-treated subjects versus 12.3% on placebo (risk ratio 2.09; 95% CI 1.57 to 2.79) [5]. The FDA Adverse Event Reporting System (FAERS) database lists acne among the top five skin-related adverse events for testosterone cypionate, with over 4,700 reports filed between 2004 and 2023 [6].

Severity varies widely. The majority of cases are mild (comedonal or papulopustular, affecting fewer than 20 lesions). Severe nodulocystic acne occurs in roughly 3% to 5% of patients [5]. "Testosterone-induced acne is dose-dependent and timing-dependent," notes Dr. Shalender Bhasin, Professor of Medicine at Harvard Medical School and principal investigator of the Testosterone Trials (TTrials). "Patients whose trough levels stay within the normal physiologic range (400 to 700 ng/dL) have significantly lower acne incidence than those running supraphysiologic" [7].

Red Flags: When to Call Your Doctor

Most testosterone-related acne is a nuisance, not a danger. But certain presentations require prompt medical evaluation. Call your prescribing physician or dermatologist if you experience any of the following.

Cystic or nodular lesions. Deep, painful lumps larger than 5 mm that do not come to a head within a week signal nodulocystic acne. This subtype carries a high risk of permanent scarring and often requires systemic therapy [8].

Signs of secondary infection. Increasing redness, warmth, purulent drainage, or fever above 100.4°F (38°C) around acne lesions suggests bacterial superinfection. Methicillin-resistant Staphylococcus aureus (MRSA) folliculitis can mimic acne on the trunk and requires culture-directed antibiotics [9].

Rapid spread to new body areas. Acne that begins on the face and quickly extends to the chest, back, and shoulders within two to three weeks may indicate supraphysiologic hormone levels. Your provider should check a mid-cycle or peak testosterone level.

Scarring. If you notice pitted or hypertrophic scars forming, early dermatologic intervention can minimize long-term cosmetic damage. Waiting increases scar depth and treatment complexity.

Emotional or psychological impact. Acne that causes social withdrawal, anxiety, or depression warrants discussion with your provider. The 2018 Endocrine Society Clinical Practice Guideline on testosterone therapy specifically recommends monitoring for psychological effects of androgenic side effects and adjusting therapy accordingly [10].

Failure of first-line treatment. If eight weeks of consistent topical therapy (benzoyl peroxide plus a topical retinoid) produces no improvement, escalation to oral antibiotics or isotretinoin may be needed.

Managing Acne While Staying on TRT

The goal is controlling acne without discontinuing testosterone therapy. Stopping TRT resolves acne in most cases, but it also reverses the benefits. A stepwise approach works for the majority of patients.

Step 1: Optimize your testosterone protocol. Switching from biweekly 200 mg injections to weekly 100 mg injections (or even twice-weekly 50 mg injections) flattens peak-to-trough fluctuations. A 2020 study in Translational Andrology and Urology showed that men who switched from biweekly to weekly cypionate dosing had a 41% reduction in acne lesion counts over 12 weeks [11]. Subcutaneous injection of the same cypionate formulation may also produce more stable levels than intramuscular delivery [12].

Step 2: Start topical therapy. The American Academy of Dermatology (AAD) guidelines recommend benzoyl peroxide (2.5% to 5%) combined with a topical retinoid (adapalene 0.1% or tretinoin 0.025%) as first-line for mild-to-moderate acne [13]. Apply benzoyl peroxide in the morning and the retinoid at night. Results take six to eight weeks. Use oil-free, non-comedogenic moisturizers and sunscreen daily.

Step 3: Consider oral therapy for moderate-to-severe cases. Doxycycline 100 mg daily for 8 to 12 weeks reduces inflammatory lesions. For severe nodulocystic acne, isotretinoin at 0.25 to 0.5 mg/kg/day for 4 to 6 months is the most effective option, producing complete remission in over 85% of patients [14]. Monthly liver function and lipid panels are required during isotretinoin treatment. Concurrent testosterone therapy is not a contraindication to isotretinoin, though close lipid monitoring is advisable since both agents can raise triglycerides.

Step 4: Adjunctive measures. Shower within 30 minutes of exercise. Use a salicylic acid (2%) body wash on the chest, shoulders, and back. Change bed linens at least twice per week. Avoid anabolic steroid stacking, which dramatically worsens acne through supraphysiologic androgen exposure.

The Role of Dose and Delivery Method

Testosterone dose is the single strongest predictor of acne severity on TRT. The Testosterone Trials (TTrials), which enrolled 790 men aged 65 and older, found that dermatologic adverse events (including acne) occurred more frequently in men whose testosterone levels exceeded 800 ng/dL on therapy [15]. The Endocrine Society guideline recommends targeting mid-normal testosterone levels (450 to 600 ng/dL) to balance symptomatic benefit against side-effect risk [10].

Delivery method matters. Transdermal testosterone (gels and patches) produces flatter pharmacokinetic curves than intramuscular injections. A comparative analysis of 1,084 men in the Journal of Urology (2017) showed acne rates of 15.8% with topical gel versus 28.4% with intramuscular cypionate (P <0.01) [16]. The tradeoff: gels carry a risk of interpersonal transfer, require daily application, and cost more without insurance.

For patients committed to injections, smaller, more frequent doses are the simplest intervention. The half-life of testosterone cypionate is approximately eight days, making weekly or twice-weekly protocols pharmacokinetically rational [2]. Your provider can also check estradiol levels. Aromatization of testosterone to estradiol does not directly cause acne, but elevated estradiol may prompt some clinicians to prescribe aromatase inhibitors, which can indirectly affect skin by altering the androgen-to-estrogen ratio.

Acne vs. Folliculitis: Telling the Difference

Not every bump on TRT is acne. Bacterial folliculitis, pityrosporum (fungal) folliculitis, and contact dermatitis can mimic hormonal acne. Distinguishing these conditions matters because treatment differs.

Acne vulgaris presents as comedones (blackheads and whiteheads), papules, and pustules concentrated on the face, upper back, and chest. Folliculitis appears as uniform, monomorphic papules and pustules centered on hair follicles, often pruritic rather than painful. Pityrosporum folliculitis tends to cluster on the trunk and does not respond to antibiotics. It requires antifungal therapy (oral fluconazole 200 mg weekly for 2 to 4 weeks or topical ketoconazole) [17].

If your breakout itches rather than hurts, does not include comedones, or fails to improve with standard acne therapy after six weeks, ask your provider about a KOH preparation or bacterial culture to rule out non-acne diagnoses. "I see testosterone patients misdiagnosed with acne when they actually have pityrosporum folliculitis at least once a month," states Dr. Joshua Zeichner, Associate Professor of Dermatology at Mount Sinai Hospital. "The treatment is completely different, so accurate diagnosis is the first step" [18].

Long-Term Outlook and Scarring Prevention

TRT-related acne tends to peak in severity between months 3 and 6 of therapy. After the sebaceous glands adapt to stable androgen levels, many patients see spontaneous improvement by months 9 to 12, even without changing their testosterone dose [4]. This temporal pattern parallels the natural history of pubertal acne, where peak sebum production eventually downregulates through receptor desensitization.

Scarring, however, is permanent. The risk of scarring correlates with inflammation duration, lesion depth, and mechanical manipulation (picking or squeezing). A prospective cohort study in the British Journal of Dermatology found that early intervention with topical retinoids within four weeks of acne onset reduced scarring incidence by 47% compared to delayed treatment (P <0.001; N=120) [19].

Patients who develop scars despite treatment have several options. Microneedling, fractional CO2 laser resurfacing, and subcision are the best-studied interventions for atrophic (pitted) scars. Intralesional triamcinolone (10 to 40 mg/mL) flattens hypertrophic and keloidal scars. These procedures should wait until active acne is fully controlled to prevent new scar formation in treated areas.

Monitoring Labs While Treating Acne on TRT

Your provider should order specific labs to guide both testosterone dosing and acne management. The baseline panel before starting TRT should include total testosterone, free testosterone, sex hormone-binding globulin (SHBG), DHT, estradiol, complete blood count, hepatic panel, and lipid profile [10].

Once acne develops, additional timing-specific labs help. A peak testosterone level drawn 48 to 72 hours after injection and a trough level drawn the morning before the next injection define your peak-to-trough ratio. If the peak exceeds 1,100 ng/dL or the trough drops below 300 ng/dL, dose or frequency adjustment is indicated. A serum DHT level above 80 ng/dL may warrant discussion about 5-alpha reductase inhibitors (finasteride 1 mg daily), which can reduce acne at the cost of potential sexual side effects [20].

If your provider prescribes isotretinoin, expect monthly fasting lipid panels and liver function tests. Testosterone cypionate itself can raise hematocrit, so a CBC every 6 to 12 months remains part of routine TRT monitoring per Endocrine Society recommendations [10].